High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.

Uganda adopted the integrase inhibitor dolutegravir (DTG) as part its preferred first-line HIV treatment regimen in 2018. Prior to the national rollout, the Uganda Ministry of Health and Clinton Health Access Initiative (CHAI) launched a pilot study in July 2017 aimed at better understanding patient...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Vennie Mbaziira Nabitaka, Pamela Nawaggi, Jennifer Campbell, James Conroy, Joseph Harwell, Kinanga Magambo, Caroline Middlecote, Benvy Caldwell, Cordelia Katureebe, Norah Namuwenge, Rita Atugonza, Andrew Musoke, Joshua Musinguzi
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2020-01-01
Serija:	PLoS ONE
Online dostop:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0232419&type=printable
Oznake:	Označite Brez oznak, prvi označite!